Screening of Lysosomal Storage Disorders Diseases in Minority Groups
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03812042|
Recruitment Status : Unknown
Verified January 2019 by Lysosomal and Rare Disorders Research and Treatment Center, Inc..
Recruitment status was: Active, not recruiting
First Posted : January 22, 2019
Last Update Posted : January 22, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Lysosomal Storage Diseases||Diagnostic Test: Enzyme assay and molecular sequencing|
Lysosomes are small, cytoplasmic organelles that contain several acid hydrolase enzymes. These enzymes break down foreign materials and cellular debris allowing the lysosomes to act as recycling centers for the cells. Following DNA transcription, lysosomal enzymes are produced in the endoplasmic reticulum and targeted to lysosomes by specific recognition markers. If one of the enzymes is absent or if its function is diminished due to either an altered amino acid sequence of the protein or defective intracellular trafficking, the macromolecules metabolized by the specific enzyme will gradually accumulate in the lysosomes. Abnormal substrate storage leads to cellular dysfunction followed by cell death ultimately manifesting as tissue damage and organ failure.
More than 50 metabolic disorders resulting from defective lysosomal enzyme function have been described and are classified as lysosomal storage disorders (LSDs). Although individually uncommon (less than 1 in 100,000), the combined incidence of this group of genetic disorders is about 1 in 5,000 to 1 in 10,000. The prevalence might be even higher than predicted due to undiagnosed instances or misdiagnosis of milder cases.
Most of LSDs are inherited in an autosomal recessive manner except two disorders: Fabry disease and Hunter syndrome, which are X chromosome linked. Two healthy carriers of the same autosomal recessive disease may have an affected child. Usually the carriers are unaware of their carrier status prior to screening or until they have a sick child. These disorders are more common in communities with high consanguinity and where cousin marriages are allowed. In the case of X-linked diseases, the mutant gene is passed down from one generation to the next one in a specific way. If a male has an abnormal copy of the specific gene, he will show the typical presentation of the disease. If a woman has an abnormal copy of the specific gene, she may develop some milder symptoms of the disease due to random X- inactivation.
Screening for LSDs is performed by measuring enzymatic activity in peripheral blood. The most cost effective and convenient way is to use dried filter paper blood spots. A positive screening result has to be followed by a confirmatory enzymatic testing using white blood cells, plasma or cultured skin fibroblasts and/or DNA mutation analysis. The importance of screening for LSDs has been recognized by several state governments as these tests are being included in many newborn screening programs. Although newborn screening helps to identify patients early on, there is still an unmet need for population screening and for identifying patients with reversible tissue damage. LSDs cause serious and progressive problems with multiple body systems. Therapy is available and is promising in most cases. Importantly, patients with LSDs require thorough management plans for their complex health issues.
|Study Type :||Observational|
|Estimated Enrollment :||100000 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Enzymatic and Genotypic Screening of Lysosomal Storage Diseases in Minority Groups|
|Actual Study Start Date :||March 17, 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
Diagnostic Test: Enzyme assay and molecular sequencing
Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
- Enzyme activity analysis to identify subjects with Lysosomal storage disorders [ Time Frame: 5 years ]To identify patients with LSDs using enzymatic activity specific to individual lysosomal storage disorders using left-over blood of blood samples collected as part of standard clinical care.
- Genotypic analysis of subjects with abnormal enzyme activity [ Time Frame: 5 years ]Samples from subjects with abnormally low enzyme activity will be used for targeted sequencing analysis to diagnose any pathologic mutations.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
To be enrolled in this study the subject must meet the following (inclusion) criteria:
- Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age
- Subject is managed by a physician in the Washington, D.C and Richmond, VA metro area
- Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run
subjects must not meet any of the following (exclusion) criteria:
- Absolute contraindication for blood drawing
- Subject cannot be traced back by the referring physician upon a positive screening result
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03812042
|United States, Virginia|
|Fairfax, Virginia, United States, 22030|
|Principal Investigator:||Renuka Limgala, PhD||LDRTC|
|Principal Investigator:||Margarita M Ivanova, PhD||LDRTC|
|Principal Investigator:||Ozlem Goker-Alpan, MD||LDRTC|
|Responsible Party:||Lysosomal and Rare Disorders Research and Treatment Center, Inc.|
|Other Study ID Numbers:||
|First Posted:||January 22, 2019 Key Record Dates|
|Last Update Posted:||January 22, 2019|
|Last Verified:||January 2019|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Lysosomal Storage Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn